Baird Financial Group
CORT icon

Baird Financial Group’s Corcept Therapeutics CORT Stock Holding History

Baird Financial Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,859
Closed -$1.17M – 1760
2024
Q2 		$1.17M Buy
35,859
+3,638
+11% +$99.7K ﹤0.01% 1116
2024
Q1 		$812K Buy
+32,221
New +$761K ﹤0.01% 1222
2023
Q4 		– Sell
-23,274
Closed -$634K – 1725
2023
Q3 		$634K Buy
+23,274
New +$674K ﹤0.01% 1251
2023
Q2 		– Sell
-21,841
Closed -$473K – 1699
2023
Q1 		$473K Buy
21,841
+4,773
+28% +$105K ﹤0.01% 1335
2022
Q4 		$347K Buy
17,068
+7,651
+81% +$192K ﹤0.01% 1410
2022
Q3 		$241K Buy
+9,417
New +$252K ﹤0.01% 1539
2019
Q4 		– Sell
-127,828
Closed -$1.81M – 1512
2019
Q3 		$1.81M Sell
127,828
-19,108
-13% -$235K 0.01% 802
2019
Q2 		$1.64M Buy
+146,936
New +$1.64M 0.01% 836

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Baird Financial Group's CORT Position: Q3 2024 in Review

Baird Financial Group sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 35,859 shares — an estimated $1.17M sold.

Baird Financial Group first reported a position in CORT in Q2 2019 and held it in 8 quarters. The position peaked at $1.81M in Q3 2019. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Baird Financial Group reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baird Financial Group sold 35,859 Corcept Therapeutics shares in Q3 2024, an estimated $1.17M.
  • Baird Financial Group first reported a position in Corcept Therapeutics in Q2 2019 and held it in 8 quarters.
  • Baird Financial Group's Corcept Therapeutics position peaked at $1.81M in Q3 2019.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Baird Financial Group's 13F filing for Q3 2024, filed 14 Nov 2024.